EU Non-Human Primate Opinion Is A “Tremendous Missed Opportunity”
Executive Summary
An opinion from a European Commission committee on using non-human primates in pharmaceutical research is being criticized as a missed opportunity that wastes time in developing new models of biomedical research.
You may also be interested in...
Work To Replace, Reduce And Refine But Use Of Non-Human Primates In Research Still Necessary, Says EU Panel
Non-human primates will have to continue to be used in biomedical research for the foreseeable future, according to the European Commission’s Scientific Committee on Health Environmental and Emerging Risks. A ban would stall scientific progress but work should continue under the replacing, reducing and refining approach, the panel says.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.